Author

M. Carre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

E. Pasquier· 2 shared M. Le Grand· 2 shared M. Rossi· 2 shared M.-P. Montero· 2 shared N. ANDRE· 2 shared B. Mouysset· 1 shared C. Carrere· 1 shared C. Colin· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

E. Pasquier

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

J. Ariey-Bonnet, R. Berges, M.-P. Montero, B. Mouysset, P. Piris, K. Muller, G. Pinna, T. W. Failes, G. M. Arndt, N. Baeza-Kallee, C. Colin, O. Chinot, D. Braguer, X. Morelli, N. ANDRE, , E. Pasquier

This study identifies synergistic drug combinations for glioblastoma by screening core vulnerabilities and validating them in preclinical models.

bioRxiv · Dec 14, 2022Pharmacology & Toxicology

Metronomic therapy prevents emergence of drug resistance by maintaining the dynamic of intratumor heterogeneity.

M. Bondarenko, M. Le Grand, Y. Shaked, Z. Raviv, G. Chapuisat, C. Carrere, M.-P. Montero, M. Rossi, E. Pasquier, M. Carre, N. Andre

This study shows metronomic therapy better controls tumor heterogeneity than maximum-tolerated dose by leveraging drug-sensitive clones' suppressive effect on resistant ones through paracrine mechanisms.

bioRxiv · Jan 4, 2021 · PreprintCancer Biology

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells via modulating metabolism and death pathways.

J. Vial, P. Huchede, S. Fagault, F. Basset, M. Rossi, J. Geoffray, J. Bisaccia, M. Creveaux, D. Neves, F. Fauvelle, P. Castets, M. Carre, K. Weber, M. Castets

This study shows that low ANT1 expression in rhabdomyosarcoma cells promotes oncogenic properties by altering metabolism and death pathways, and restoring ANT1 sensitizes cells to chemotherapy.

bioRxiv · Mar 3, 2020Cancer Biology